human 22rv1 primary pca cell line Search Results


deposit no 203480  (ATCC)
99
ATCC deposit no 203480
Deposit No 203480, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/22Rv1/us07098312-3977-23-22
Average 99 stars, based on 1 article reviews
deposit no 203480 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
lncap  (ATCC)
97
ATCC lncap
Lncap, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/VCaP/pmc07226055-163-9-16
Average 97 stars, based on 1 article reviews
lncap - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
human prostate cancer cells  (ATCC)
95
ATCC human prostate cancer cells
Human Prostate Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/Human+Prostate+Cancer+Cells%2C+NE-1-8+cells/us07744878-870-5-10
Average 95 stars, based on 1 article reviews
human prostate cancer cells - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
human prostate cell lines  (ATCC)
99
ATCC human prostate cell lines
Human Prostate Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/293T/pmc08842993-145-0-21
Average 99 stars, based on 1 article reviews
human prostate cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
human pca cell lines  (ATCC)
99
ATCC human pca cell lines
Human Pca Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/DU+145/pmc07840735-31-0-20
Average 99 stars, based on 1 article reviews
human pca cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
crl 1978 22rv1 prostate atcc crl 2505 du 145 prostate atcc htb 81 lncap  (ATCC)
97
ATCC crl 1978 22rv1 prostate atcc crl 2505 du 145 prostate atcc htb 81 lncap
Crl 1978 22rv1 Prostate Atcc Crl 2505 Du 145 Prostate Atcc Htb 81 Lncap, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/ES-2/pmc11399272__42003_2024_6839_MOESM1_ESM-257-270-273
Average 97 stars, based on 1 article reviews
crl 1978 22rv1 prostate atcc crl 2505 du 145 prostate atcc htb 81 lncap - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
prostate cancer cell line  (ATCC)
96
ATCC prostate cancer cell line
Prostate Cancer Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/22Rv1%3B+Prostate+Carcinoma%3B+Human/pmc03192035-285-20-24
Average 96 stars, based on 1 article reviews
prostate cancer cell line - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier
22rv1  (DSMZ)
94
DSMZ 22rv1
22rv1, supplied by DSMZ, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/22RV1/pmc11024179-266-21-34
Average 94 stars, based on 1 article reviews
22rv1 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
lncap atcc human prostate cancer  (ATCC)
95
ATCC lncap atcc human prostate cancer
Lncap Atcc Human Prostate Cancer, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/C4-2%3B+Prostate+Cancer%3B+Human/pmc11969731__12929_2025_1135_MOESM3_ESM-3-162-163
Average 95 stars, based on 1 article reviews
lncap atcc human prostate cancer - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
cell line pz-hpv-7  (BioResource International Inc)
90
BioResource International Inc cell line pz-hpv-7
AGEs promote cell proliferation and decrease sensitivity to chemodrugs in PCa cells. (A) Androgen-dependent LNCaP and <t>22rv1,</t> and (B) androgen-independent DU145 and PC3 cells were treated for 48 h with five types of AGEs-BSA (10–500 μg/mL) derived from different glycated agents. Cell viability was measured using the MTS assay and expressed as a relative percentage of the BSA control. GA-derived and GOA-derived AGEs increased PCa cell proliferation, whereas the other AGEs failed to enhance cell proliferation. (C) Treatment with anti-RAGE antibodies inhibited GA-derived AGEs-induced cell proliferation. PCa cells were co-treated with GA-derived AGE and anti-RAGE antibodies (10 μg/mL) for 48 h. Treatment of (D) AGEs-BSA (500 μg/mL) and (E) AGE compounds increased resistance to chemodrug toxicity in PCa cells. The cells were co-treated with AGEs and DTX (7.2 μM) for 24 h, and the cell viability was measured. GA-derived and GOA-derived AGEs, CEL, and CML increased PCa cell survival in response to the DTX challenge. (F) sRAGE counteracted CML-mediated chemoresistance and rendered PCa cells more sensitive to DTX toxicity. The cells were preincubated with sRAGE for 24 h, after which DTX was added and incubated for another 24 h. Data shown represents the means ± SD from three independent experiments with 6–8 replicates each. *P < 0.05 when compared with the BSA or vehicle control. DTX, docetaxel; anti-RAGE ab, anti-RAGE antibody; sRAGE, soluble RAGE.
Cell Line Pz Hpv 7, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/22rv1/pmc10962675-104-1-36
Average 90 stars, based on 1 article reviews
cell line pz-hpv-7 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
human prostate cancer cell lines  (ATCC)
99
ATCC human prostate cancer cell lines
AGEs promote cell proliferation and decrease sensitivity to chemodrugs in PCa cells. (A) Androgen-dependent LNCaP and <t>22rv1,</t> and (B) androgen-independent DU145 and PC3 cells were treated for 48 h with five types of AGEs-BSA (10–500 μg/mL) derived from different glycated agents. Cell viability was measured using the MTS assay and expressed as a relative percentage of the BSA control. GA-derived and GOA-derived AGEs increased PCa cell proliferation, whereas the other AGEs failed to enhance cell proliferation. (C) Treatment with anti-RAGE antibodies inhibited GA-derived AGEs-induced cell proliferation. PCa cells were co-treated with GA-derived AGE and anti-RAGE antibodies (10 μg/mL) for 48 h. Treatment of (D) AGEs-BSA (500 μg/mL) and (E) AGE compounds increased resistance to chemodrug toxicity in PCa cells. The cells were co-treated with AGEs and DTX (7.2 μM) for 24 h, and the cell viability was measured. GA-derived and GOA-derived AGEs, CEL, and CML increased PCa cell survival in response to the DTX challenge. (F) sRAGE counteracted CML-mediated chemoresistance and rendered PCa cells more sensitive to DTX toxicity. The cells were preincubated with sRAGE for 24 h, after which DTX was added and incubated for another 24 h. Data shown represents the means ± SD from three independent experiments with 6–8 replicates each. *P < 0.05 when compared with the BSA or vehicle control. DTX, docetaxel; anti-RAGE ab, anti-RAGE antibody; sRAGE, soluble RAGE.
Human Prostate Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/PC-3/pm36978001-79-1-24
Average 99 stars, based on 1 article reviews
human prostate cancer cell lines - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
human prostate adenocarcinoma  (ATCC)
97
ATCC human prostate adenocarcinoma
AGEs promote cell proliferation and decrease sensitivity to chemodrugs in PCa cells. (A) Androgen-dependent LNCaP and <t>22rv1,</t> and (B) androgen-independent DU145 and PC3 cells were treated for 48 h with five types of AGEs-BSA (10–500 μg/mL) derived from different glycated agents. Cell viability was measured using the MTS assay and expressed as a relative percentage of the BSA control. GA-derived and GOA-derived AGEs increased PCa cell proliferation, whereas the other AGEs failed to enhance cell proliferation. (C) Treatment with anti-RAGE antibodies inhibited GA-derived AGEs-induced cell proliferation. PCa cells were co-treated with GA-derived AGE and anti-RAGE antibodies (10 μg/mL) for 48 h. Treatment of (D) AGEs-BSA (500 μg/mL) and (E) AGE compounds increased resistance to chemodrug toxicity in PCa cells. The cells were co-treated with AGEs and DTX (7.2 μM) for 24 h, and the cell viability was measured. GA-derived and GOA-derived AGEs, CEL, and CML increased PCa cell survival in response to the DTX challenge. (F) sRAGE counteracted CML-mediated chemoresistance and rendered PCa cells more sensitive to DTX toxicity. The cells were preincubated with sRAGE for 24 h, after which DTX was added and incubated for another 24 h. Data shown represents the means ± SD from three independent experiments with 6–8 replicates each. *P < 0.05 when compared with the BSA or vehicle control. DTX, docetaxel; anti-RAGE ab, anti-RAGE antibody; sRAGE, soluble RAGE.
Human Prostate Adenocarcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+22rv1+primary+pca+cell+line/PC-3%3B+Prostate+Adenocarcinoma%3B+Human/pmc06466739-69-0-11
Average 97 stars, based on 1 article reviews
human prostate adenocarcinoma - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

Image Search Results


AGEs promote cell proliferation and decrease sensitivity to chemodrugs in PCa cells. (A) Androgen-dependent LNCaP and 22rv1, and (B) androgen-independent DU145 and PC3 cells were treated for 48 h with five types of AGEs-BSA (10–500 μg/mL) derived from different glycated agents. Cell viability was measured using the MTS assay and expressed as a relative percentage of the BSA control. GA-derived and GOA-derived AGEs increased PCa cell proliferation, whereas the other AGEs failed to enhance cell proliferation. (C) Treatment with anti-RAGE antibodies inhibited GA-derived AGEs-induced cell proliferation. PCa cells were co-treated with GA-derived AGE and anti-RAGE antibodies (10 μg/mL) for 48 h. Treatment of (D) AGEs-BSA (500 μg/mL) and (E) AGE compounds increased resistance to chemodrug toxicity in PCa cells. The cells were co-treated with AGEs and DTX (7.2 μM) for 24 h, and the cell viability was measured. GA-derived and GOA-derived AGEs, CEL, and CML increased PCa cell survival in response to the DTX challenge. (F) sRAGE counteracted CML-mediated chemoresistance and rendered PCa cells more sensitive to DTX toxicity. The cells were preincubated with sRAGE for 24 h, after which DTX was added and incubated for another 24 h. Data shown represents the means ± SD from three independent experiments with 6–8 replicates each. *P < 0.05 when compared with the BSA or vehicle control. DTX, docetaxel; anti-RAGE ab, anti-RAGE antibody; sRAGE, soluble RAGE.

Journal: Journal of Food and Drug Analysis

Article Title: Biological and clinical significance of the AGE-RAGE axis in the aggressiveness and prognosis of prostate cancer

doi: 10.38212/2224-6614.3475

Figure Lengend Snippet: AGEs promote cell proliferation and decrease sensitivity to chemodrugs in PCa cells. (A) Androgen-dependent LNCaP and 22rv1, and (B) androgen-independent DU145 and PC3 cells were treated for 48 h with five types of AGEs-BSA (10–500 μg/mL) derived from different glycated agents. Cell viability was measured using the MTS assay and expressed as a relative percentage of the BSA control. GA-derived and GOA-derived AGEs increased PCa cell proliferation, whereas the other AGEs failed to enhance cell proliferation. (C) Treatment with anti-RAGE antibodies inhibited GA-derived AGEs-induced cell proliferation. PCa cells were co-treated with GA-derived AGE and anti-RAGE antibodies (10 μg/mL) for 48 h. Treatment of (D) AGEs-BSA (500 μg/mL) and (E) AGE compounds increased resistance to chemodrug toxicity in PCa cells. The cells were co-treated with AGEs and DTX (7.2 μM) for 24 h, and the cell viability was measured. GA-derived and GOA-derived AGEs, CEL, and CML increased PCa cell survival in response to the DTX challenge. (F) sRAGE counteracted CML-mediated chemoresistance and rendered PCa cells more sensitive to DTX toxicity. The cells were preincubated with sRAGE for 24 h, after which DTX was added and incubated for another 24 h. Data shown represents the means ± SD from three independent experiments with 6–8 replicates each. *P < 0.05 when compared with the BSA or vehicle control. DTX, docetaxel; anti-RAGE ab, anti-RAGE antibody; sRAGE, soluble RAGE.

Article Snippet: The human PCa cell lines 22rv1 and LNCaP (androgen-dependent), DU145 and PC3 (androgen-independent), CA-HPV-10 (prostatic adenocarcinoma of Gleason grade 4/4), and PZ-HPV-7 (epithelial cells from the peripheral zone of the normal prostate) were obtained from the Bioresource Collection and Research Center (Food Industry Research and Development Institute, Taiwan).

Techniques: Derivative Assay, MTS Assay, Control, Incubation